Immunological processes of enhancers and suppressors of long non-coding RNAs associated with brain tumors and inflammation

References

• Neugut AI, Sackstein P, Hillyer GC, et al. Magnetic resonance imaging-based screening for asymptomatic brain tumors: a review. Oncologist 2019;24(3):375–384. doi:10.1634/theoncologist.2018-0177.[PMC]
   PubMed Web of Science ®Google Scholar
• Kumar RL, Kakarla J, Isunuri BV, et al. Multi-class brain tumor classification using residual network and global average pooling. Multimed Tools Appl 2021;80(9):13429–13438. doi:10.1007/s11042-020-10335-4.
   Web of Science ®Google Scholar
• Rasheed S, Rehman K, Akash MSH. An insight into the risk factors of brain tumors and their therapeutic interventions. Biomed Pharmacother 2021;143:112119. doi:10.1016/j.biopha.2021.112119.
   PubMed Web of Science ®Google Scholar
• Sevenich L. Brain-resident microglia and blood-borne macrophages orchestrate central nervous system inflammation in neurodegenerative disorders and brain cancer. Front Immunol 2018;9:697. doi:10.3389/fimmu.2018.00697.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Gunn MD, Fecci PE, et al. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 2020;20(1):12–25. doi:10.1038/s41568-019-0224-7.
   PubMed Web of Science ®Google Scholar
• Domingues P, González-Tablas M, Otero Á, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun 2016;53:1–15. doi:10.1016/j.bbi.2015.07.019.
   PubMed Web of Science ®Google Scholar
• Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med 2019;18(3):121–126. doi:10.4103/aam.aam_56_18.
   PubMed Web of Science ®Google Scholar
• Alghamri MS, McClellan BL, Hartlage CS, et al. Targeting neuroinflammation in brain cancer: uncovering mechanisms, pharmacological targets, and neuropharmaceutical developments. Front Pharmacol 2021;12:680021. doi:10.3389/fphar.2021.680021.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Chen X, Lv Q, et al. A novel inflammatory lncRNAs prognostic signature for predicting the prognosis of low-grade glioma patients. Front Genet 2021;12:697819–697819. doi:10.3389/fgene.2021.697819.
   PubMedGoogle Scholar
• Ghasemi S, Xu S, Nabavi SM, et al. Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). Phytother Res 2021;35(7):3649–3664. doi:10.1002/ptr.7059.
   PubMed Web of Science ®Google Scholar
• Pop S, Enciu A-M, Necula LG, et al. Long non-coding RNAs in brain tumours: focus on recent epigenetic findings in glioma. J Cell Mol Med 2018;22(10):4597–4610. doi:10.1111/jcmm.13781.
   PubMed Web of Science ®Google Scholar
• Pisignano G, Ladomery M. Post-transcriptional regulation through long non-coding RNAs (lncRNAs). Noncoding RNA 2021;7(2):29. doi:10.3390/ncrna7020029.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhu X, Huang S. Extracellular vesicle long non-coding RNAs and circular RNAs: biology, functions and applications in cancer. Cancer Lett 2020;489:111–120. doi:10.1016/j.canlet.2020.06.006.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Pillai PP. Current insights on extracellular vesicle-mediated glioblastoma progression: implications in drug resistance and epithelial-mesenchymal transition. Biochim Biophys Acta Gen Subj 2022;1866(3):130065. doi:10.1016/j.bbagen.2021.130065.
   PubMed Web of Science ®Google Scholar
• Razmkhah F, Soleimani M, Ghasemi S, et al. MicroRNA-21 over expression in umbilical cord blood hematopoietic stem progenitor cells by leukemia microvesicles. Genet Mol Biol 2019;42(2):465–471. doi:10.1590/1678-4685-GMB-2018-0073.
   PubMed Web of Science ®Google Scholar
• Razmkhah F, Ghasemi S, Soleimani M, et al. LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles. Exp Hematol Oncol 2019;8(1):23. doi:10.1186/s40164-019-0147-8.
   PubMed Web of Science ®Google Scholar
• Mahjoum S, Rufino-Ramos D, Pereira de Almeida L, et al. Living Proof of Activity of Extracellular Vesicles in the Central Nervous System. Int J Mol Sci 2021;22(14):7294. doi:10.3390/ijms22147294.
   PubMed Web of Science ®Google Scholar
• Spinelli C, Adnani L, Choi D, et al. Extracellular vesicles as conduits of non-coding RNA emission and intercellular transfer in brain tumors. Noncoding RNA 2018;5(1):1. doi:10.3390/ncrna5010001.
   PubMed Web of Science ®Google Scholar
• Dang Y, Wei X, Xue L, et al. Long non-coding RNA in glioma: target miRNA and signaling pathways. Clin Lab 2018;64(6):887–894. doi:10.7754/Clin.Lab.2018.180107.
   PubMedGoogle Scholar
• Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6(1):263. doi:10.1038/s41392-021-00658-5.
   PubMed Web of Science ®Google Scholar
• Huang S, Song Z, Zhang T, et al. Identification of immune cell infiltration and immune-related genes in the tumor microenvironment of glioblastomas. Front Immunol 2020;11:585034. doi:10.3389/fimmu.2020.585034.
   PubMed Web of Science ®Google Scholar
• Tomaszewski W, Sanchez-Perez L, Gajewski TF, et al. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res 2019;25(14):4202–4210. doi:10.1158/1078-0432.CCR-18-1627.
   PubMed Web of Science ®Google Scholar
• Marozzi M, Parnigoni A, Negri A, et al. Inflammation, extracellular matrix remodeling, and proteostasis in tumor microenvironment. Int J Mol Sci 2021;22(15):8102. doi:10.3390/ijms22158102.
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, et al. Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1(3):223–236. doi:10.1007/s11481-006-9025-3.
   PubMed Web of Science ®Google Scholar
• Li X, Li L, Zhou K, et al. Glioma shapes blood–brain barrier integrity and remodels the tumor microenvironment: links with clinical features and prognosis. J Clin Med 2022;11(19):5863. doi:10.3390/jcm11195863.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang F, Xiong N, et al. Remodelling and treatment of the blood-brain barrier in glioma. Cancer Manag Res 2021;13:4217–4232. doi:10.2147/CMAR.S288720.
   PubMed Web of Science ®Google Scholar
• Jackson S, ElAli A, Virgintino D, et al. Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer’s disease. Neuro Oncol 2017;19(9):1173–1182. doi:10.1093/neuonc/nox058.
   PubMed Web of Science ®Google Scholar
• Al-Kharboosh R, et al. Inflammatory mediators in glioma microenvironment play a dual role in gliomagenesis and mesenchymal stem cell homing: implication for cellular therapy. Mayo Clin Proc Innov Qual Outcomes 2020;4(4):443–459.
   PubMedGoogle Scholar
• Tong N, He Z, Ma Y, et al. Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor-glioma therapy? Front Cell Dev Biol 2021;9:706286–706286. doi:10.3389/fcell.2021.706286.
   PubMed Web of Science ®Google Scholar
• Basheer AS, Abas F, Othman I, et al. Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: mechanistic understanding and potential therapeutic applications. Cancers 2021;13(16):4226. doi:10.3390/cancers13164226.
   PubMed Web of Science ®Google Scholar
• Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol 2020;11:1731. doi:10.3389/fimmu.2020.01731.
   PubMed Web of Science ®Google Scholar
• Mostofa AGM, Punganuru SR, Madala HR, et al. The process and regulatory components of inflammation in brain oncogenesis. Biomolecules 2017;7(2):34. doi:10.3390/biom7020034.
   PubMed Web of Science ®Google Scholar
• Wang T, Cao L, Dong X, et al. LINC01116 promotes tumor proliferation and neutrophil recruitment via DDX5-mediated regulation of IL-1β in glioma cell. Cell Death Dis 2020;11(5):302. doi:10.1038/s41419-020-2506-0.
   PubMed Web of Science ®Google Scholar
• Kai K, Komohara Y, Esumi S, et al. Macrophage/microglia-derived IL-1β induces glioblastoma growth via the STAT3/NF-κB pathway. Hum Cell 2022;35(1):226–237. doi:10.1007/s13577-021-00619-8.
   PubMed Web of Science ®Google Scholar
• Li S, Jiang M, Wang L, et al. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: recent advancement. Biomed Pharmacother 2020;129:110389. doi:10.1016/j.biopha.2020.110389.
   PubMed Web of Science ®Google Scholar
• Monteleone NJ, Lutz CS. miR-708 negatively regulates TNFα/IL-1β signaling by suppressing NF-κB and arachidonic acid pathways. Mediators Inflamm 2021;2021:5595520.
   PubMed Web of Science ®Google Scholar
• Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008;28(2):185–200. doi:10.1002/med.20101.
   PubMed Web of Science ®Google Scholar
• Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells 2019;8(11):1398. doi:10.3390/cells8111398.
   PubMed Web of Science ®Google Scholar
• Tan MSY, Sandanaraj E, Chong YK, et al. A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nat Commun 2019;10(1):3601. doi:10.1038/s41467-019-11614-x.
   PubMedGoogle Scholar
• Yeo ECF, Brown MP, Gargett T, et al. The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cells 2021;10(3):607. doi:10.3390/cells10030607.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang J, Zhang Z, et al. Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction. Cell Death Dis 2021;12(4):373. doi:10.1038/s41419-021-03664-1.
   PubMed Web of Science ®Google Scholar
• Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation 2018;15(1):290. doi:10.1186/s12974-018-1330-2.
   PubMed Web of Science ®Google Scholar
• Hao Y, Baker D, ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci 2019;20(11):2767. doi:10.3390/ijms20112767.
   PubMed Web of Science ®Google Scholar
• Zhang G, Feng W, Wu J. Down-regulation of SEPT9 inhibits glioma progression through suppressing TGF-β-induced epithelial-mesenchymal transition (EMT). Biomed Pharmacother 2020;125:109768. doi:10.1016/j.biopha.2019.109768.
   PubMed Web of Science ®Google Scholar
• Tang F, Wang H, Chen E, et al. LncRNA-ATB promotes TGF-β-induced glioma cells invasion through NF-κB and P38/MAPK pathway. J Cell Physiol 2019;234(12):23302–23314. doi:10.1002/jcp.28898.
   PubMed Web of Science ®Google Scholar
• García-Hernández L, García-Ortega MB, Ruiz-Alcalá G, et al. The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci 2021;23(1):370. doi:10.3390/ijms23010370.
   PubMed Web of Science ®Google Scholar
• Guo X, Sui R, Piao H. Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma. J Nanobiotechnology 2022;20(1):383. doi:10.1186/s12951-022-01584-6.
   PubMed Web of Science ®Google Scholar
• Yang E, Wang X, Gong Z, et al. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther 2020;5(1):242. doi:10.1038/s41392-020-00359-5.
   PubMed Web of Science ®Google Scholar
• Wu Y, Niu D, Deng S, et al. Tumor-derived or non-tumor-derived exosomal noncodingRNAs and signaling pathways in tumor microenvironment. Int Immunopharmacol 2022;106:108626. doi:10.1016/j.intimp.2022.108626.
   PubMed Web of Science ®Google Scholar
• Wang T, Nasser MI, Shen J, et al. Functions of exosomes in the triangular relationship between the tumor, inflammation, and immunity in the tumor microenvironment. J Immunol Res 2019;2019:4197829–4197810. doi:10.1155/2019/4197829.
   PubMed Web of Science ®Google Scholar
• Mahinfar P, Baradaran B, Davoudian S, et al. Long non-coding RNAs in multidrug resistance of glioblastoma. Genes 2021;12(3):455. doi:10.3390/genes12030455.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiao L, Lu L, et al. The mechanisms underlying the beneficial effects of stem cell-derived exosomes in repairing ischemic tissue injury. J Cardiovasc Transl Res 2022;15(3):524–534. doi:10.1007/s12265-022-10263-8.
   PubMed Web of Science ®Google Scholar
• Movahedpour A, Khatami SH, Khorsand M, et al. Exosomal noncoding RNAs: key players in glioblastoma drug resistance. Mol Cell Biochem 2021;476(11):4081–4092. doi:10.1007/s11010-021-04221-2.
   PubMed Web of Science ®Google Scholar
• Lin X, Luo M-L, Song E. Long non-coding RNA and non-coding nucleic acids: signaling players in the networks of the tumor ecosystem. Cell Insight 2022;1(1):100004. doi:10.1016/j.cellin.2022.100004.
   PubMedGoogle Scholar
• Xie T, Li B, Liu H, et al. Long non-coding RNA as a potential biomarker for prognosis of glioma: a protocol for systematic review and meta-analysis. Medicine 2021;100(33):e26921-e26921. doi:10.1097/MD.0000000000026921.
   Web of Science ®Google Scholar
• Nie J-H, Li T-X, Zhang X-Q, et al. Roles of non-coding RNAs in normal human brain development, brain tumor, and neuropsychiatric disorders. Noncoding RNA 2019;5(2):36. doi:10.3390/ncrna5020036.
   PubMed Web of Science ®Google Scholar
• Wu Y, Qian Z. Long non-coding RNAs (lncRNAs) and microRNAs regulatory pathways in the tumorigenesis and pathogenesis of glioma. Discov Med 2019;28(153):129–138.
   PubMed Web of Science ®Google Scholar
• Dong D, Mu Z, Zhao C, et al. ZFAS1: a novel tumor-related long non-coding RNA. Cancer Cell Int 2018;18(1):125. doi:10.1186/s12935-018-0623-y.
   PubMedGoogle Scholar
• Katsushima K, Natsume A, Ohka F, et al. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun 2016;7(1):13616. doi:10.1038/ncomms13616.
   PubMedGoogle Scholar
• Han Y, Wu Z, Wu T, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis 2016;7(3):e2123-e2123–e2123. doi:10.1038/cddis.2015.407.
   Google Scholar
• Li J, Zhou L. Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/β-catenin signaling. Biomed Pharmacother 2018;102:602–607. doi:10.1016/j.biopha.2018.03.116.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei D-L, Wan L, et al. Highly expressed lncRNA CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling. Biochem Biophys Res Commun 2017;482(4):1219–1225. doi:10.1016/j.bbrc.2016.12.016.
   PubMed Web of Science ®Google Scholar
• Gao XF, He HQ, Zhu XB, et al. LncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway. Neoplasma 2019;66(4):532–542. doi:10.4149/neo_2018_180829n656.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhou Y, Liu M, et al. Long non-coding RNA LINC00470 in serum derived exosome: a critical regulator for proliferation and autophagy in glioma cells. Cancer Cell Int 2021;21(1):149. doi:10.1186/s12935-021-01825-y.
   PubMed Web of Science ®Google Scholar
• Wang H, Li L, Yin L. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway. Biochem Biophys Res Commun 2018;500(2):518–524. doi:10.1016/j.bbrc.2018.04.133.
   PubMed Web of Science ®Google Scholar
• Ji J, Xu R, Ding K, et al. Long noncoding RNA SChLAP1 forms a growth-promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling. Clin Cancer Res 2019;25(22):6868–6881. doi:10.1158/1078-0432.CCR-19-0747.
   PubMed Web of Science ®Google Scholar
• Vallée A, Lecarpentier Y, Guillevin R, et al. Opposite interplay between the canonical WNT/β-catenin pathway and PPAR gamma: a potential therapeutic target in gliomas. Neurosci Bull 2018;34(3):573–588. doi:10.1007/s12264-018-0219-5.
   PubMed Web of Science ®Google Scholar
• Vallée A, Lecarpentier Y, Vallée J-N. Opposed interplay between IDH1 mutations and the WNT/β-catenin pathway: added information for glioma classification. Biomedicines 2021;9(6):619. doi:10.3390/biomedicines9060619.
   PubMed Web of Science ®Google Scholar
• Cheng C, Dong Y, Ru X, et al. LncRNA ANCR promotes glioma cells invasion, migration, proliferation and inhibits apoptosis via interacting with EZH2 and repressing PTEN expression. Cancer Gene Ther 2021;28(9):1025–1034. doi:10.1038/s41417-020-00263-8.
   PubMed Web of Science ®Google Scholar
• Chen M, Yin X, Lu C, et al. Mahanine induces apoptosis, cell cycle arrest, inhibition of cell migration, invasion and PI3K/AKT/mTOR signalling pathway in glioma cells and inhibits tumor growth in vivo. Chem Biol Interact 2019;299:1–7. doi:10.1016/j.cbi.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Ebrahimpour A, Sarfi M, Rezatabar S, et al. Novel insights into the interaction between long non-coding RNAs and microRNAs in glioma. Mol Cell Biochem 2021;476(6):2317–2335. doi:10.1007/s11010-021-04080-x.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 2018;18(5):309–324. doi:10.1038/nri.2017.142.
   PubMed Web of Science ®Google Scholar
• Xu X, Liang Y, Gareev I, et al. LncRNA as potential biomarker and therapeutic target in glioma. Mol Biol Rep 2023;50(1):841–851. doi:10.1007/s11033-022-08056-y.
   PubMed Web of Science ®Google Scholar
• Gong X, Huang M-Y. Tumor-suppressive function of lncRNA-MEG3 in glioma cells by regulating miR-6088/SMARCB1 axis. Biomed Res Int 2020;2020:4309161–4309115. doi:10.1155/2020/4309161.
   PubMed Web of Science ®Google Scholar
• He Z, Long J, Yang C, et al. LncRNA DGCR5 plays a tumor-suppressive role in glioma via the miR-21/Smad7 and miR-23a/PTEN axes. Aging 2020;12(20):20285–20307. doi:10.18632/aging.103800.
   PubMedGoogle Scholar
• Sheng J, He X, Yu W, et al. p53-Targeted lncRNA ST7-AS1 acts as a tumour suppressor by interacting with PTBP1 to suppress the Wnt/β-catenin signalling pathway in glioma. Cancer Lett 2021;503:54–68. doi:10.1016/j.canlet.2020.12.039.
   PubMed Web of Science ®Google Scholar
• Chae Y, Roh J, Kim W. The roles played by long non-coding RNAs in glioma resistance. Int J Mol Sci 2021;22(13):6834. doi:10.3390/ijms22136834.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Riillo C, Scionti F, et al. miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy. Cancers 2021;13(7):1587. doi:10.3390/cancers13071587.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Lim K-H, Yang S, et al. Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets. J Hematol Oncol 2021;14(1):77. doi:10.1186/s13045-021-01088-0.
   PubMed Web of Science ®Google Scholar
• Li X, Sun L, Wang X, et al. A five immune-related lncRNA signature as a prognostic target for glioblastoma. Front Mol Biosci 2021;8:632837. doi:10.3389/fmolb.2021.632837.
   PubMed Web of Science ®Google Scholar
• Wang X, Gao M, Ye J, et al. An immune gene-related five-lncRNA signature for to predict glioma prognosis. Front Genet 2020;11:612037. doi:10.3389/fgene.2020.612037.
   PubMed Web of Science ®Google Scholar
• Peng L, Chen Z, Chen Y, et al. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med 2019;8(17):7161–7173. doi:10.1002/cam4.2583.
   PubMed Web of Science ®Google Scholar
• Zheng J, Liu X, Wang P, et al. CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 Axis. Mol Ther 2016;24(7):1199–1215. doi:10.1038/mt.2016.71.
   PubMed Web of Science ®Google Scholar
• Hu Y, Luo H, Zhu X, et al. CRNDE/ETS1/GPR17 facilitates the proliferation, migration, and invasion of glioma. Comput Math Methods Med 2021;2021:7566365–7566311. doi:10.1155/2021/7566365.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Abbas M, Ullah MF, et al. Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: micromanaging by not so small non-coding RNAs. Semin Cancer Biol 2022;85:155–163. doi:10.1016/j.semcancer.2021.07.015.
   PubMed Web of Science ®Google Scholar
• Tian Y, Ke Y-Q, Ma Y. Immune-related lncRNA correlated with transcription factors provide strong prognostic prediction in gliomas. J Oncol 2020;2020:2319194–2319112. doi:10.1155/2020/2319194.
   PubMed Web of Science ®Google Scholar
• Lu Y, Sha H, Sun X, et al. CRNDE: an oncogenic long non-coding RNA in cancers. Cancer Cell Int 2020;20(1):162. doi:10.1186/s12935-020-01246-3.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yin M, Peng G, et al. CRNDE: an important oncogenic long non-coding RNA in human cancers. Cell Prolif 2018;51(3):e12440. doi:10.1111/cpr.12440.
   PubMed Web of Science ®Google Scholar
• Zhong C, Tao B, Li X, et al. HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis. Cell Death Dis 2022;13(2):160. doi:10.1038/s41419-021-04471-4.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu X-J, Li Y, et al. Prognostic value of immune-related lncRNA SBF2-AS1 in diffuse lower-grade glioma. Technol Cancer Res Treat 2021;20:15330338211011966–15330338211011966. doi:10.1177/15330338211011966.
   Web of Science ®Google Scholar
• Lu Q, Lou J, Cai R, et al. Emerging roles of a pivotal lncRNA SBF2-AS1 in cancers. Cancer Cell Int 2021;21(1):417. doi:10.1186/s12935-021-02123-3.
   PubMed Web of Science ®Google Scholar
• Guo X-D, Ji J, Xue T-F, et al. FTY720 exerts anti-glioma effects by regulating the glioma microenvironment through increased CXCR4 internalization by glioma-associated microglia. Front Immunol 2020;11:178. doi:10.3389/fimmu.2020.00178.
   PubMed Web of Science ®Google Scholar
• Tang T, Wang L-X, Yang M-L, et al. lncRNA TPTEP1 inhibits stemness and radioresistance of glioma through miR‑106a‑5p‑mediated P38 MAPK signaling. Mol Med Rep 2020;22(6):4857–4867. doi:10.3892/mmr.2020.11542.
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhao H, Xiao X, et al. Long non-coding RNA MALAT1 upregulates ZEB2 expression to promote malignant progression of glioma by attenuating miR-124. Mol Neurobiol 2021;58(3):1006–1016. doi:10.1007/s12035-020-02165-0.
   PubMed Web of Science ®Google Scholar
• Yang J, Sun G, Hu Y, et al. Extracellular vesicle lncRNA metastasis-associated lung adenocarcinoma transcript 1 released from glioma stem cells modulates the inflammatory response of microglia after lipopolysaccharide stimulation through regulating miR-129-5p/high mobility group box-1 protein axis. Front Immunol 2019;10:3161. doi:10.3389/fimmu.2019.03161.
   PubMed Web of Science ®Google Scholar
• Shi T, Guo D, Xu H, et al. HOTAIRM1, an enhancer lncRNA, promotes glioma proliferation by regulating long-range chromatin interactions within HOXA cluster genes. Mol Biol Rep 2020;47(4):2723–2733. doi:10.1007/s11033-020-05371-0.
   PubMed Web of Science ®Google Scholar
• Liang Q, Li X, Guan G, et al. Long non-coding RNA, HOTAIRM1, promotes glioma malignancy by forming a ceRNA network. Aging 2019;11(17):6805–6838. doi:10.18632/aging.102205.
   PubMedGoogle Scholar
• Ding H, Cui L, Wang C. Long noncoding RNA LIFR-AS1 suppresses proliferation, migration and invasion and promotes apoptosis through modulating miR-4262/NF-κB pathway in glioma. Neurol Res 2021;43(3):210–219. doi:10.1080/01616412.2020.1836465.
   PubMed Web of Science ®Google Scholar
• Xia S, Ji R, Zhan W. Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits proliferation and invasion of glioma cells by suppressing the Wnt/β-catenin signaling pathway. BMC Neurol 2017;17(1):30. doi:10.1186/s12883-017-0813-6.
   PubMedGoogle Scholar
• Guo H, Hu G, Yang Q, et al. Knockdown of long non-coding RNA CCAT2 suppressed proliferation and migration of glioma cells. Oncotarget 2016;7(49):81806–81814. doi:10.18632/oncotarget.13242.
   PubMedGoogle Scholar
• Astaneh M, Ghafouri-Fard S. Long non-coding RNAs as regulators of Wnt/β catenin pathway. Gene Reports 2019;16:100404. doi:10.1016/j.genrep.2019.100404.
   Web of Science ®Google Scholar
• Gong X, Huang M. Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/β-catenin signal pathway. Cancer Gene Ther 2017;24(9):381–385. doi:10.1038/cgt.2017.32.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen X, Tang G, et al. AS-IL 6 promotes glioma cell invasion by inducing H3K27Ac enrichment at the IL 6 promoter and activating IL 6 transcription. FEBS Lett 2016;590(24):4586–4593. doi:10.1002/1873-3468.12485.
   PubMed Web of Science ®Google Scholar
• Ke J, Yao Y-l, Zheng J, et al. Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326. Oncotarget 2015;6(26):21934–21949. doi:10.18632/oncotarget.4290.
   PubMedGoogle Scholar
• Cao S, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Rese 2016;6(11):2561.
   PubMed Web of Science ®Google Scholar
• Wang P, Peng X, Zhang J, et al. LncRNA-135528 inhibits tumor progression by up-regulating CXCL10 through the JAK/STAT pathway. Apoptosis 2018;23(11–12):651–666. doi:10.1007/s10495-018-1482-7.
   PubMed Web of Science ®Google Scholar
• Hu Y-W, Kang C-M, Zhao J-J, et al. Lnc RNA PLAC 2 down-regulates RPL 36 expression and blocks cell cycle progression in glioma through a mechanism involving STAT 1. J Cell Mol Med 2018;22(1):497–510. doi:10.1111/jcmm.13338.
   PubMed Web of Science ®Google Scholar
• Katsushima K, Jallo G, Eberhart CG, et al. Long non-coding RNAs in brain tumors. NAR Cancer 2021;3(1):zcaa041. doi:10.1093/narcan/zcaa041.
   PubMedGoogle Scholar
• Shang C, Guo Y, Hong Y, et al. Long non-coding RNA TUSC7, a target of miR-23b, plays tumor-suppressing roles in human gliomas. Front Cell Neurosci 2016;10:235. doi:10.3389/fncel.2016.00235.
   PubMed Web of Science ®Google Scholar
• Dai J, Ma J, Yu B, et al. Long noncoding RNA TUNAR represses growth, migration, and invasion of human glioma cells through regulating miR-200a and Rac1. Oncol Res 2018;27(1):107–115. doi:10.3727/096504018X15205622257163.
   PubMed Web of Science ®Google Scholar
• Wang A, Meng M, Zhao X, et al. Long non-coding RNA ENST00462717 suppresses the proliferation, survival, and migration by inhibiting MDM2/MAPK pathway in glioma. Biochem Biophys Res Commun 2017;485(2):513–521. doi:10.1016/j.bbrc.2017.02.015.
   PubMed Web of Science ®Google Scholar
• Han M, Wang S, Fritah S, et al. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling. Brain 2020;143(2):512–530. doi:10.1093/brain/awz406.
   PubMed Web of Science ®Google Scholar
• Gao R, Zhang R, Zhang C, et al. Long noncoding RNA CCAT1 promotes cell proliferation and metastasis in human medulloblastoma via MAPK pathway. Tumori Journal 2018;104(1):43–50. doi:10.5301/tj.5000662.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu G, Zeng W, et al. Long noncoding RNA AB073614 promotes the malignance of glioma by activating Wnt/β-catenin signaling through downregulating SOX7. Oncotarget 2017;8(39):65577–65587. doi:10.18632/oncotarget.19305.
   PubMedGoogle Scholar
• Guo A, et al. Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway. Histol Histopathol 2022;37(6);543–554.
   Web of Science ®Google Scholar
• Gao X, Guo X, Xue H, et al. lncTCF7 is a negative prognostic factor, and knockdown of lncTCF7 inhibits migration, proliferation and tumorigenicity in glioma. Sci Rep 2017;7(1):17456. doi:10.1038/s41598-017-17340-y.
   PubMedGoogle Scholar
• Yang Y, Ren M, Song C, et al. LINC00461, a long non-coding RNA, is important for the proliferation and migration of glioma cells. Oncotarget 2017;8(48):84123–84139. doi:10.18632/oncotarget.20340.
   PubMedGoogle Scholar
• Zhu Z, Dai J, Liao Y, et al. Knockdown of long noncoding RNA LINC00152 suppresses cellular proliferation and invasion in glioma cells by regulating miR-4775. Oncol Res 2018;26(6):857–867. doi:10.3727/096504017X15016337254597.
   PubMed Web of Science ®Google Scholar
• Liu H, Li C, Yang J, et al. Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis. J Cell Mol Med 2018;22(12):6338–6344. doi:10.1111/jcmm.13932.
   PubMed Web of Science ®Google Scholar
• Wang R, Li Y, Zhu G, et al. Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathway. Neuropsychiatr Dis Treat 2017;13:1805–1813. doi:10.2147/NDT.S137171.
   PubMed Web of Science ®Google Scholar
• Liang J, Liu N, Xin H. Knockdown long non-coding RNA PEG10 inhibits proliferation, migration and invasion of glioma cell line U251 by regulating miR-506. Gen Physiol Biophys 2019;38(4):295–304. doi:10.4149/gpb_2019018.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu B, Ma H. Long non-coding RNA GHET1 promotes viability, migration and invasion of glioma cell line U251 by down-regulation of miR-216a. Eur Rev Med Pharmacol Sci 2019;23(4):1591–1599.
   PubMed Web of Science ®Google Scholar
• Liu B, Cao W, Ma H. Knockdown of lncRNA LSINCT5 suppresses growth and metastasis of human glioma cells via up-regulating miR-451. Artif Cells Nanomed Biotechnol 2019;47(1):2507–2515. doi:10.1080/21691401.2019.1626404.
   PubMed Web of Science ®Google Scholar
• Zheng J, Li X-d, Wang P, et al. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget 2015;6(28):25339–25355. doi:10.18632/oncotarget.4509.
   PubMedGoogle Scholar
• Chen W-L, Chen H-J, Hou G-Q, et al. LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma. Aging 2019;11(16):6053–6068. doi:10.18632/aging.102162.
   PubMedGoogle Scholar
• Li B, Zhao H, Song J, et al. LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis. Hum Cell 2020;33(1):159–174. doi:10.1007/s13577-019-00281-1.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhou G, Li M, et al. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway. Neurochem Int 2018;118:233–241. doi:10.1016/j.neuint.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Cai H, Xue Y, Wang P, et al. The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. Oncotarget 2015;6(23):19759–19779. doi:10.18632/oncotarget.4331.
   PubMedGoogle Scholar
• Cai H, Liu X, Zheng J, et al. Long non-coding RNA taurine upregulated 1 enhances tumor-induced angiogenesis through inhibiting microRNA-299 in human glioblastoma. Oncogene 2017;36(3):318–331. doi:10.1038/onc.2016.212.
   PubMed Web of Science ®Google Scholar
• Li J, An G, Zhang M, et al. Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells. Biochem Biophys Res Commun 2016;477(4):743–748. doi:10.1016/j.bbrc.2016.06.129.
   PubMed Web of Science ®Google Scholar
• Gong W, Zheng J, Liu X, et al. Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e. Oncotarget 2016;7(38):62208–62223. doi:10.18632/oncotarget.11403.
   PubMedGoogle Scholar
• Zhen L, Yun-Hui L, Hong-Yu D, et al. Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis. Tumour Biol 2016;37(1):673–683. doi:10.1007/s13277-015-3843-y.
   PubMedGoogle Scholar
• Yang X, Xiao Z, Du X, et al. Silencing of the long non-coding RNA NEAT1 suppresses glioma stem-like properties through modulation of the miR-107/CDK6 pathway. Oncol Rep 2017;37(1):555–562. doi:10.3892/or.2016.5266.
   PubMed Web of Science ®Google Scholar
• Wu W, Yu T, Wu Y, et al. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res 2019;38(1):1–14. doi:10.1186/s13046-019-1132-0.
   PubMedGoogle Scholar
• Tang J, Yu B, Li Y, et al. TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity. EMBO Rep 2019;20(12):e48170. doi:10.15252/embr.201948170.
   PubMed Web of Science ®Google Scholar
• He Z, You C, Zhao D. Long non-coding RNA UCA1/miR-182/PFKFB2 axis modulates glioblastoma-associated stromal cells-mediated glycolysis and invasion of glioma cells. Biochem Biophys Res Commun 2018;500(3):569–576. doi:10.1016/j.bbrc.2018.04.091.
   PubMed Web of Science ®Google Scholar
• Cai J, Zhang J, Wu P, et al. Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/NF-κB pathway. J Neurooncol 2018;140(2):225–236. doi:10.1007/s11060-018-2951-0.
   PubMed Web of Science ®Google Scholar
• Ren J, Yang Y, Xue J, et al. Long noncoding RNA SNHG7 promotes the progression and growth of glioblastoma via inhibition of miR-5095. Biochem Biophys Res Commun 2018;496(2):712–718. doi:10.1016/j.bbrc.2018.01.109.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Y, Yu T, et al. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol 2017;19(9):1195–1205. doi:10.1093/neuonc/nox017.
   PubMed Web of Science ®Google Scholar
• Yu H, Zheng J, Liu X, et al. Transcription factor NFAT5 promotes glioblastoma cell-driven angiogenesis via SBF2-AS1/miR-338-3p-mediated EGFL7 expression change. Front Mol Neurosci 2017;10:301. doi:10.3389/fnmol.2017.00301.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Wang S, et al. SP1-induced lncRNA ZFPM2 antisense RNA 1 (ZFPM2-AS1) aggravates glioma progression via the miR-515-5p/Superoxide dismutase 2 (SOD2) axis. Bioengineered 2021;12(1):2299–2310. doi:10.1080/21655979.2021.1934241.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Zheng H, et al. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. J Exp Clin Cancer Res 2019;38(1):1–13. doi:10.1186/s13046-019-1371-0.
   PubMed Web of Science ®Google Scholar
• Lu C, Wei Y, Wang X, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. p. Mol Cancer 2020;19(1):28. doi:10.1186/s12943-020-1137-5.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhou J, Wang C, et al. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. Cell Death Dis 2020;11(5):384. doi:10.1038/s41419-020-2540-y.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu R, Li Q, et al. SNHG1/miR-556-5p/TCF12 feedback loop enhances the tumorigenesis of meningioma through Wnt signaling pathway. J Cell Biochem 2020;121(2):1880–1889. doi:10.1002/jcb.29423.
   PubMed Web of Science ®Google Scholar
• Li T, Ren J, Ma J, et al. LINC00702/miR-4652-3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathway. Biomed Pharmacother 2019;113:108718. doi:10.1016/j.biopha.2019.108718.
   PubMed Web of Science ®Google Scholar
• Xu Z, Sun Y, Wang D, et al. SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells. Cancer Cell Int 2020;20(1):236. doi:10.1186/s12935-020-01291-y.
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X, Hu C, et al. Shiny transcriptional junk: lncRNA-derived peptides in cancers and immune responses. Life Sci 2023;316:121434. doi:10.1016/j.lfs.2023.121434.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wu H, Zhang M. Long non-coding RNA: an underlying bridge linking neuroinflammation and central nervous system diseases. Neurochem Int 2021;148:105101. doi:10.1016/j.neuint.2021.105101.
   PubMed Web of Science ®Google Scholar
• Li N, Shi K, Li W. TUSC7: a novel tumor suppressor long non-coding RNA in human cancers. J Cell Physiol 2018;233(9):6401–6407. doi:10.1002/jcp.26544.
   PubMed Web of Science ®Google Scholar
• Tan X, Jiang H, Fang Y, et al. The essential role of long non-coding RNA GAS5 in glioma: interaction with microRNAs, chemosensitivity and potential as a biomarker. J Cancer 2021;12(1):224–231. doi:10.7150/jca.49203.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yu W, Zhu S, et al. Long noncoding RNA GAS5 regulates the proliferation, migration, and invasion of glioma cells by negatively regulating miR-18a-5p. J Cell Physiol 2018;234(1):757–768. doi:10.1002/jcp.26889.
   PubMed Web of Science ®Google Scholar
• Wang X-P, Shan C, Deng X-L, et al. Long non-coding RNA PAR5 inhibits the proliferation and progression of glioma through interaction with EZH2. Oncol Rep 2017;38(5):3177–3186. doi:10.3892/or.2017.5986.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Lin Z, Li X, et al. Inflammatory cytokine IL6 cooperates with CUDR to aggravate hepatocyte-like stem cells malignant transformation through NF-κB signaling. Sci Rep 2016;6(1):36843. doi:10.1038/srep36843.
   PubMedGoogle Scholar
• Yeh JE, Frank DA. STAT3-interacting proteins as modulators of transcription factor function: implications to targeted cancer therapy. ChemMedChem 2016;11(8):795–801. doi:10.1002/cmdc.201500482.
   PubMed Web of Science ®Google Scholar
• Jia L, Tian Y, Chen Y, et al. The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-catenin pathway. Onco Targets Ther 2018;11:313–321. doi:10.2147/OTT.S154339.
   PubMed Web of Science ®Google Scholar
• Guo LP, et al. Influences of LncRNA SNHG20 on proliferation and apoptosis of glioma cells through regulating the PTEN/PI3K/AKT signaling pathway. Eur Rev Med Pharmacol Sci 2019;23(1):253–261.
   PubMed Web of Science ®Google Scholar
• Chen W, Li Q, Zhang G, et al. LncRNA HOXA-AS3 promotes the malignancy of glioblastoma through regulating miR-455-5p/USP3 axis. J Cell Mol Med 2020;24(20):11755–11767. doi:10.1111/jcmm.15788.
   PubMed Web of Science ®Google Scholar
• Tripathi, Shraddha, Shree, Bakhya, Mohapatra, Stuti, et al., The expanding regulatory mechanisms and cellular functions of long non-coding RNAs (lncRNAs) in neuroinflammation.Mol Neurobiol, 2021. 58(6): p 2916–2939. doi:10.1007/s12035-020-02268-8.
   PubMed Web of Science ®Google Scholar
• Chu L, Yu L, Liu J, et al. Long intergenic non-coding LINC00657 regulates tumorigenesis of glioblastoma by acting as a molecular sponge of miR-190a-3p. Aging 2019;11(5):1456–1470. doi:10.18632/aging.101845.
   PubMedGoogle Scholar
• Guo A, Fang G, Lin Z, et al. Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-kappaB signaling pathway. Histol Histopathol 2022;37(6):543–554.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang W, Wu Z, et al. Over-expression of lncRNA TMEM161B-AS1 promotes the malignant biological behavior of glioma cells and the resistance to temozolomide via up-regulating the expression of multiple ferroptosis-related genes by sponging hsa-miR-27a-3p. Cell Death Discov 2021;7(1):311. doi:10.1038/s41420-021-00709-4.
   PubMed Web of Science ®Google Scholar
• Zhang B, Fang S, Cheng Y, et al. The long non-coding RNA, urothelial carcinoma associated 1, promotes cell growth, invasion, migration, and chemo-resistance in glioma through Wnt/β-catenin signaling pathway. Aging 2019;11(19):8239–8253. doi:10.18632/aging.102317.
   PubMedGoogle Scholar
• Ghafouri-Fard S, Hajiesmaeili M, Shoorei H, et al. The impact of lncRNAs and miRNAs in regulation of function of cancer stem cells and progression of cancer. Front Cell Dev Biol 2021;9:696820. doi:10.3389/fcell.2021.696820.
   PubMed Web of Science ®Google Scholar
• Wu X, Yang L, Wang J, et al. The Involvement of Long Non-Coding RNAs in Glioma: from Early Detection to Immunotherapy. Front Immunol 2022;13:897754. doi:10.3389/fimmu.2022.897754.
   PubMed Web of Science ®Google Scholar
• He X, Qi Y, Zhang X, et al. Current landscape of tumor-derived exosomal ncRNAs in glioma progression, detection, and drug resistance. Cell Death Dis 2021;12(12):1145. doi:10.1038/s41419-021-04430-z.
   PubMed Web of Science ®Google Scholar
• Eades G, Zhang Y-S, Li Q-L, et al. Long non-coding RNAs in stem cells and cancer. World J Clin Oncol 2014;5(2):134–141. doi:10.5306/wjco.v5.i2.134.
   PubMedGoogle Scholar
• Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest 2019;129(8):3006–3017. doi:10.1172/JCI127201.
   PubMed Web of Science ®Google Scholar
• Ni Y, Zhou X, Yang J, et al. The role of tumor-stroma interactions in drug resistance within tumor microenvironment. Front Cell Dev Biol 2021;9:637675. doi:10.3389/fcell.2021.637675.
   PubMed Web of Science ®Google Scholar
• Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012;81(1):145–166. doi:10.1146/annurev-biochem-051410-092902.
   PubMed Web of Science ®Google Scholar
• Winkle M, El-Daly SM, Fabbri M, et al. Noncoding RNA therapeutics—challenges and potential solutions. Nat Rev Drug Discov 2021;20(8):629–651. doi:10.1038/s41573-021-00219-z.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhong S, Shen Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 2011;12(2):95–105. doi:10.4161/cbt.12.2.15952.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Thiruvengadam M, Venkidasamy B, et al. Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: current status and future perspectives. Semin Cancer Biol 2022;86(Pt 2):678–696. doi:10.1016/j.semcancer.2022.04.005.
   PubMedGoogle Scholar
• Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 2012;4(3):a006049.
   PubMed Web of Science ®Google Scholar
• Cadwell K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. Nat Rev Immunol 2016;16(11):661–675. doi:10.1038/nri.2016.100.
   PubMed Web of Science ®Google Scholar
• Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018;9(6):7204–7218. doi:10.18632/oncotarget.23208.
   PubMedGoogle Scholar
• Han Li C, Chen Y. Small and long non-coding RNAs: novel targets in perspective cancer therapy. Curr Genomics 2015;16(5):319–326. doi:10.2174/1389202916666150707155851.
   PubMed Web of Science ®Google Scholar
• Park E-G, Pyo S-J, Cui Y, et al. Tumor immune microenvironment lncRNAs. Brief Bioinform 2022;23(1):bbab504. doi:10.1093/bib/bbab504.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-2634.
   PubMed Web of Science ®Google Scholar
• Wilusz JE. Long noncoding RNAs: re-writing dogmas of RNA processing and stability. Biochim Biophys Acta 2016;1859(1):128–138. doi:10.1016/j.bbagrm.2015.06.003.
   PubMed Web of Science ®Google Scholar
• Yadav B, Pal S, Rubstov Y, et al. LncRNAs associated with glioblastoma: from transcriptional noise to novel regulators with a promising role in therapeutics. Mol Ther Nucleic Acids 2021;24:728–742. doi:10.1016/j.omtn.2021.03.018.
   PubMedGoogle Scholar
• Li J, Zhao J, Tan T, et al. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J Nanomedicine 2020;15:2563–2582. doi:10.2147/IJN.S243223.
   PubMed Web of Science ®Google Scholar
• Ratti M, Lampis A, Ghidini M, et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol 2020;15(3):261–278. doi:10.1007/s11523-020-00717-x.
   PubMed Web of Science ®Google Scholar
• Mehdipour G, Wintrasiri MN, Ghasemi S. CPP-based bioactive drug delivery to penetrate the blood-brain barrier: a potential therapy for glioblastoma multiforme. Curr Drug Targets 2022;23(7):719–728. doi:10.2174/1389450123666220207143750.
   PubMed Web of Science ®Google Scholar
• Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet 2018;392(10145):432–446. doi:10.1016/S0140-6736(18)30990-5.
   PubMed Web of Science ®Google Scholar
• Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol 2019;16(8):509–520. doi:10.1038/s41571-019-0177-5.
   PubMed Web of Science ®Google Scholar
• Latowska J, Grabowska A, Zarębska Ż, et al. Non-coding RNAs in brain tumors, the contribution of lncRNAs, circRNAs, and snoRNAs to cancer development—their diagnostic and therapeutic potential. Int J Mol Sci 2020;21(19):7001. doi:10.3390/ijms21197001.
   PubMed Web of Science ®Google Scholar
• Boussiotis VA, Charest A. Immunotherapies for malignant glioma. Oncogene 2018;37(9):1121–1141. doi:10.1038/s41388-017-0024-z.
   PubMed Web of Science ®Google Scholar
• Pancholi S, Tripathi A, Bhan A, et al. Emerging concepts on the role of extracellular vesicles and its cargo contents in glioblastoma-microglial crosstalk. Mol Neurobiol 2022;59(5):2822–2837. doi:10.1007/s12035-022-02752-3.
   PubMed Web of Science ®Google Scholar
• Chew CL, Conos SA, Unal B, et al. Noncoding RNAs: master regulators of inflammatory signaling. Trends Mol Med 2018;24(1):66–84. doi:10.1016/j.molmed.2017.11.003.
   PubMed Web of Science ®Google Scholar
• He L, Zhou H, Zeng Z, et al. Wnt/β-catenin signaling cascade: a promising target for glioma therapy. J Cell Physiol 2019;234(3):2217–2228. doi:10.1002/jcp.27186.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Glassy MC, Abak A, et al. The interaction between miRNAs/lncRNAs and Notch pathway in human disorders. Biomed Pharmacother 2021;138:111496. doi:10.1016/j.biopha.2021.111496.
   PubMed Web of Science ®Google Scholar
• Shi J, Dong B, Cao J, et al. Long non-coding RNA in glioma: signaling pathways. Oncotarget 2017;8(16):27582–27592. doi:10.18632/oncotarget.15175.
   PubMedGoogle Scholar
• Chen Y, Jin Y, Wu N. Role of tumor-derived extracellular vesicles in glioblastoma. Cells 2021;10(3):512. doi:10.3390/cells10030512.
   PubMed Web of Science ®Google Scholar
• Simon T, Jackson E, Giamas G. Breaking through the glioblastoma micro-environment via extracellular vesicles. Oncogene 2020;39(23):4477–4490. doi:10.1038/s41388-020-1308-2.
   PubMed Web of Science ®Google Scholar